News & Events
Published On: 11/10/2016
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data
CHAPEL HILL, NC – November 10, 2016 / PR NEWSWIRE / – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce two new collaborations with Bristol-Myers Squibb (BMY) to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access to a robust disease state registry that is also linked to a biorepository and patient reported outcomes, providing unique data and insights compared to typical patient registries.
“The unique collaboration with Bristol-Myers Squibb across both NASH and HCC will ensure that we are able to further provide the hepatology and oncology community with important insights across multiple conditions affecting the liver, especially as these conditions continue to develop into growing public health issues,” said Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions. The impact of the TARGET platform will help pharmaceutical partners better understand multiple elements of disease etiology, treatment modalities, and outcomes.
TARGET-NASH’s first patient enrollment occurred August 1, 2016. The company plans on enrolling up to 15,000 patients, at up to 100 sites worldwide. TARGET-HCC’s first patient enrollment is set for Q4 2016. The company plans on enrolling up to 5,000 patients worldwide, at up to 75 sites in the US and Europe.
TARGET PharmaSolutions was formed in February 2015 and currently has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 10,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
12/04/2023Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
11/10/2023Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases